Results 31 to 40 of about 82,094 (282)

Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention. [PDF]

open access: yes, 2014
Cardiovascular disease remains one of the largest contributors to death worldwide. Improvements in cardiovascular technology leading to the current generation of drug-eluting stents, bioresorbable stents, and drug-eluting balloons, coupled with advances ...
Panitch, Alyssa, Scott, Rebecca A
core   +2 more sources

In Stent Restenosis Predictors after Carotid Artery Stenting

open access: yesStroke Research and Treatment, 2010
Purpose. The long-term efficacy of carotid artery stenting is debated. Predictors of stent restenosis are not fully investigated. Our aim was to assess the incidence of long term restenosis after CAS and to identify some predictors of restenosis. Methods.
Mirco Cosottini   +7 more
doaj   +1 more source

A novel ultrafast-low-dose computed tomography protocol allows concomitant coronary artery evaluation and lung cancer screening [PDF]

open access: yes, 2018
BACKGROUND:Cardiac computed tomography (CT) is often performed in patients who are at high risk for lung cancer in whom screening is currently recommended.
Bandiera, A   +10 more
core   +1 more source

Role of noncoding RNA in vascular remodelling [PDF]

open access: yes, 2016
Purpose of review: Noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) are becoming fundamentally important in the pathophysiology relating to injury-induced vascular remodelling.
Baker, Andrew H.   +2 more
core   +1 more source

Local Therapy for Restenosis [PDF]

open access: yesEuropean Journal of Vascular and Endovascular Surgery, 2005
The durability of all forms of open or percutaneous revascularisation is affected by the development of localised stenoses within the bypass graft or at the site of endarterectomy, stent or angioplasty. The reported incidence of significant restenosis has varied dependent on initial procedure, site, case mix and definition, but is greatest during the ...
Golledge, J., Campbell, J. H.
openaire   +3 more sources

The predictive value of preprocedural laboratory data in patients with coronary artery restenosis in various types of stents

open access: yesРоссийский кардиологический журнал, 2019
Aim. To identify the effect of preprocedural laboratory parameters on the occurrence of in-stent restenosis in various types of stents, to assess the significance of gender, age and various forms of coronary artery disease (CAD) as risk factors for ...
D. V. Shames   +3 more
doaj   +1 more source

Emotions and scope effects in the monetary valuation of health [PDF]

open access: yes, 2018
JEL classifications: H41 H51 I11 I18 I31This study presents evidence on the role of emotions in the monetary evaluation of health technologies, namely, drug-eluting stents (DES) in our case.
Araña, Jorge   +3 more
core   +1 more source

Restenosis [PDF]

open access: yesCirculation: Cardiovascular Interventions, 2011
In the past decade, tremendous progress has been made in reducing the incidence of restenosis with the advent of the drug-eluting stent (DES). With “plain old balloon angioplasty,” rates of acute and chronic vessel occlusion were unacceptably high at ≈30% to 60%, secondary to acute and chronic recoil and constrictive remodeling.
Bill D. Gogas   +2 more
openaire   +4 more sources

Paclitaxel eluting stents versus bare metal stents restenosis

open access: yesRevista Cubana de Medicina Militar, 2021
Introduction: The restenosis of the paclitaxel-eluting stents used in Cuba has not been studied. Objective: To evaluate the restenosis of paclitaxel-eluting stents and conventional stents.
Ronald Aroche Aportela   +5 more
doaj  

Bindarit inhibits human coronary artery smooth muscle cell proliferation, migration and phenotypic switching [PDF]

open access: yes, 2012
Bindarit, a selective inhibitor of monocyte chemotactic proteins (MCPs) synthesis, reduces neointimal formation in animal models of vascular injury and recently has been shown to inhibit in-stent late loss in a placebo-controlled phase II clinical trial.
Angelo Guglielmotti   +12 more
core   +3 more sources

Home - About - Disclaimer - Privacy